AzTrials
AzTrials

PainNCT07663604

Assessment of Pain Experience in Fibromyalgia

An observational study of Pain and Fybromyalgia, run by Zülal TATAR at 1 site in Turkey (Türkiye).

Enrolling by invitation

Enrolling by invitation. The study team selects and invites participants, usually from an existing group of patients.

Sites and contacts
Official record
Search all trials

Trial summary

The aim of this study is to assess pain in individuals with fibromyalgia using abstract animations and graphical body maps, and to investigate the determinants of pain quality. Read more about this study

Who is it for?
Ages 18 years and older, women only
Conditions the study is for
Pain, Fybromyalgia
How many people
70 participants
Where
1 siteTurkey (Türkiye)
Study dates
3 Feb 2026to 24 Jun 2027
How long will I take part?
1 Day
Phase
Observational
Are there results?
Not yet: the study is under way

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • Women only
  • No healthy volunteers
  • Adult, Older adult

Study population: The study will be conducted on individuals followed by the Rheumatology Department of Pamukkale University Faculty of Medicine and diagnosed with Fibromyalgia according to the 2016 ACR Fibromyalgia Syndrome diagnostic criteria.

Who may be able to join

  • Being 18 years of age or older
  • Being female
  • Having a diagnosis of fibromyalgia syndrome according to the American Rheumatology Association Criteria
  • Not receiving active physiotherapy and rehabilitation treatment
  • Volunteering to participate in the study.

Who cannot join

  • Having a serious pathology or disease that could compromise the assessment process or affect clinical decision-making (metastasis, cancer, untreated or unhealed fractures, central nervous system disease or history of diabetes, pain outside the musculoskeletal system)
  • Having severe mental and psychological disorders

Trial locations and contacts

1 site in 1 country. Contact the study team or a site near you to ask about taking part.

Turkey (Türkiye)1 site
  • Pamukkale University

    Denizli, Şirnak

Other trials in Turkey (Türkiye)

About this study

Official title: Assessment of Pain Experience in Fibromyalgia Using Abstract Animations and Graphic Body Maps, and Determinants of Pain Quality

The aim of this study is to assess pain in individuals with fibromyalgia using abstract animations and graphical body maps, and to investigate the determinants of pain quality.

Conditions
Pain, Fybromyalgia
Medical subject headings
Pain

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Painimation Mobile App

    An electronic pain assessment tool designed to measure the location, nature, and intensity of pain using "pain animations and graphical images." Patients use a colorable body image to indicate the areas affected by pain. They then select from eight animations that represent their pain experiences. The size, speed, and intensity of these animations can be adjusted to accurately represent pain severity. Painimation animations are derived from the McGill Pain Questionnaire Short Form. They were developed through a human-centered design process involving patients with acute and chronic pain, clinicians, researchers, and design students. The animations correspond to the following pain qualities: "pounding," "shooting," "throbbing," "tingling," "cramping," "burning," "stabbing," and "electrifying." The area of the body affected by pain will be calculated based on the proportion of selected pixels.

    Measured: At baseline (Day 1)

Secondary outcomes (8)
  1. PainDetect Questionnaire

    The PainDetect Questionnaire is a simple, self-administered, and convenient screening questionnaire that allows for the identification of neuropathic pain components in patients with chronic pain. It consists of four main sections. The total score is calculated by summing the scores from the last three sections and ranges from -1 to 38. Scores of 12 and below indicate that the neuropathic pain component is unlikely, while scores of 19 and above indicate a high probability of the neuropathic pain component being present. Scores between 12 and 19 are considered inconclusive.

    Measured: At baseline (Day 1)

  2. Central Sensitization Scale

    The Central Sensitization Scale consists of two sections. Section A comprises 25 items that assess symptoms related to physical and emotional health commonly seen in disorders associated with central sensitization. Each item is scored on a 5-point Likert scale ranging from (0) "never" to (4) "always," with a total score of 100. Higher scores indicate a higher level of symptom presence. Section B includes 7 diagnoses assessed within the scope of central sensitization syndrome (tension-type headache or migraine, fibromyalgia, irritable bowel syndrome, restless legs syndrome, temporomandibular joint disorder, chronic fatigue syndrome, and multiple chemical sensitivities) and three additional diagnoses reported to be associated with central sensitization (depression, anxiety or panic attacks, and neck injury). Participants are asked the following question: "Have you been diagnosed by a doctor with any of the following conditions?" and the year of diagnosis is indicated.

    Measured: At baseline (Day 1)

  3. Pain Catastrophizing Scale

    The Pain Catastrophizing Scale is a scale used to assess the psychological aspects of pain-related symptoms in three dimensions: rumination, helplessness, and amplification. The scale includes 13 items related to specific emotions and thoughts defined as negative associations. Five of these items relate to rumination, six to helplessness, and two to amplification. Patients are asked how frequently they recall each thought in these items. Each item is scored between 0-4, and the total score is calculated between 0-52.

    Measured: At baseline (Day 1)

  4. Brief Pain Inventory

    The Brief Pain Inventory is a short, easy-to-administer assessment method that can be used to evaluate pain. It consists of two sections: pain intensity and impairment caused by pain. It has 4 items related to pain intensity and 7 items related to impairment caused by pain. Each item is rated on a scale of 0 to 10. The total score for both sections is calculated by summing the scores given to each item and dividing the sum by the number of questions, and ranges from 0 to 10. Higher scores indicate more pain and greater impairment caused by pain.

    Measured: At baseline (Day 1)

  5. Fatigue Severity Scale

    Published by Krupp in 1989, the FSS consists of nine items. For each item, the patient is asked to choose a number between 1 and 7 indicating how much they agree with the statement; 1 means strongly disagree, and 7 means strongly agree. Generally, scores of 4 and above indicate severe fatigue.

    Measured: At baseline (Day 1)

  6. The Short Form-12 Health Questionnaire

    A summary version of the Short Form-36 Health Questionnaire, the SF-12 can also be divided into physical and mental sections and consists of a total of 12 questions. The physical component of the scale is scored between 24 and 56 points, while the mental component is scored between 19 and 60 points. Higher scores on the scale indicate a higher quality of life.

    Measured: At baseline (Day 1)

  7. Hospital Anxiety and Depression Scale

    The Hospital Anxiety and Depression Scale is a 14-item, two-factor scale that assesses patients' anxiety and depression levels. Seven of these items assess anxiety, and the other seven assess depression. Each item is scored on a four-point scale. The total score for anxiety and depression ranges from 0 to 21. Scores between 0 and 7 indicate a normal emotional state. Scores above 7 on either the anxiety or depression subscales have been reported to indicate the presence of anxiety and depressive disorders.

    Measured: At baseline (Day 1)

  8. Revised Fibromyalgia Impact Questionnaire

    The Revised Fibromyalgia Impact Questionnaire is a questionnaire evaluating limitations and functional disability in patients with fibromyalgia. It consists of 21 questions divided into three sections: function, general, and symptoms. All questions are rated on a numerical scale from 0 to 10. A score of 70 or higher indicates severe disability in this patient group. Higher scores indicate greater fibromyalgia-related disability.

    Measured: At baseline (Day 1)

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted23 Jun 2026
  2. Study start3 Feb 2026
  3. Primary completion3 Apr 2027 (estimated)
  4. Study completion24 Jun 2027 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Other
Time perspective
Prospective
Enrolment
70 participants (estimated)
Target duration
1 Day
IDs, dates and publications
ClinicalTrials.gov ID
NCT07663604
Sponsor's protocol ID
Painanimation
Status last verified
Jun 2026
First submitted
17 Jun 2026
Last updated
23 Jun 2026
Results posted
No
FDA-regulated drug
No
FDA-regulated device
No

Questions about this trial

What is this clinical trial studying?

An observational study of Pain and Fybromyalgia, run by Zülal TATAR at 1 site in Turkey (Türkiye).

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 5 inclusion and 2 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: enrolling by invitation, as of the sponsor's last update on 23 Jun 2026. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Turkey (Türkiye). Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

This study is still under way. Results are not available in the source record yet.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Painimation Mobile App (time frame: At baseline (Day 1)). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 23 Jun 2026.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in